Tag

Lipoproteina

All articles tagged with #lipoproteina

health19 days ago•4 min saved

Hidden Lipoprotein(a) May Raise Heart Risk Even With Normal Tests

Lp(a) is a genetically determined cholesterol particle linked to higher risk of heart attack and stroke that standard tests miss. Lifestyle and most cholesterol meds don’t meaningfully lower Lp(a); newer gene-silencing therapies show large reductions in Lp(a) in trials and could reduce events if confirmed. Testing is often advised for those with a family history or unexplained risk, but for now heart health still hinges on managing LDL cholesterol, blood pressure, smoking, activity, and diet.

via SciTechDaily|

#cardiovascular-risk #genetics #health

health28 days ago•6 min saved

NIH Trial Analysis Links Lipoprotein(a) to Increased Stroke and Death Risk

A study analyzing stored plasma from 20,070 participants in the ACCORD, PEACE, and SPRINT NIH trials found elevated Lipoprotein(a) levels (>=175 nmol/L) are linked to higher residual cardiovascular risk despite standard therapy: about 31% more major adverse cardiovascular events (MACE), 49% higher cardiovascular death risk, and 64% higher stroke risk, with stronger effects in those with existing heart disease; the level was not linked to a higher risk of heart attack. Testing Lp(a) could guide risk assessment and, as new targeted therapies emerge, drive more aggressive management of cholesterol and other risk factors.

via SciTechDaily|

#cardiovascular-risk #cholesterol #health

health1 month ago•5 min saved

Elevated Lp(a) Signals Ongoing Heart Risk Despite Standard Therapy

A new analysis of 20,070 adults from NIH trials shows very high lipoprotein(a) levels (≥175 nmol/L) are linked to a greater risk of major adverse cardiovascular events—especially stroke and cardiovascular death—and this risk is strongest in people with existing heart disease, suggesting Lp(a) contributes to residual risk even with standard LDL-lowering treatments. No clear increase in heart attack risk was observed. Lp(a) is largely genetic, so testing could help refine risk and guide prevention, with emerging therapies targeting Lp(a) on the horizon.

via Medical News Today|

#cardiovascular-risk #genetics #health

biotech1 month ago•12 min saved

Lp(a) sparks biotech's next wave of cardiovascular drug development

Lipoprotein(a), a genetically driven molecule linked to heart attacks, strokes, and valve disease, is poised to become a major target in biotech as firms race to develop Lp(a)-lowering therapies using siRNA and ASO approaches. The pivotal Horizon trial of pelacarsen from Novartis/Ionis is expected to read out soon and could trigger a surge in Lp(a) testing and treatment if positive, though questions remain about its ultimate market size and whether primary prevention is feasible. Competition is intensifying, with Amgen, Lilly, AstraZeneca, and others pursuing more potent or oral options, suggesting a broad, high-stakes field regardless of Horizon's outcome.

via Fierce Biotech|

#antisense-oligonucleotides #biotech #cardiovascular-disease

heart-news2 months ago•23 min saved

New ACC/AHA Dyslipidemia Guideline Promotes Early Lifestyle Action and Risk-Tailored Therapy

The ACC, AHA and partners released an updated dyslipidemia guideline that emphasizes earlier lifestyle changes, lower LDL-C targets based on individual risk, and earlier use of lipid-lowering therapies; it introduces the PREVENT-ASCVD risk calculator for primary prevention, expands testing for lipids including lipoprotein(a) and apolipoprotein B, and recommends selective use of coronary calcium scoring to guide treatment decisions, with guidance extending to pediatric screening and different populations to reduce lifetime ASCVD risk.

via www.heart.org|

#coronary-calcium-scoring #dyslipidemia #heart-news

health3 months ago•47 min saved

Soap Star Melissa Claire Egan Speaks Out on Coronary Heart Disease Diagnosis

Melissa Claire Egan, known for The Young and the Restless, revealed she was diagnosed with coronary heart disease in late January after a heart calcium scan found mild plaque in her LAD artery; she emphasizes early detection and urges other women to get evaluated, including Lipoprotein(a) and ApoB testing, and to seek heart-health screening alongside awareness efforts with the American Heart Association.

via Soap Opera Digest|

#apob #coronary-heart-disease #health

health5 months ago•2 min saved

Top Indicators and Lifestyle Tips to Prevent Heart Attacks in Young Adults

Neurologist Dr. Priyanka Sehrawat emphasizes that normal cholesterol levels do not necessarily indicate low heart attack risk, highlighting two key markers—ApoB and Lipoprotein(a)—as stronger predictors of cardiovascular events, especially in individuals with a family history or metabolic dysfunction.

via Hindustan Times|

#apob #cholesterol #health

health1 year ago•6 min saved

Unveiling Lipoprotein(a): The Hidden Heart Risk Factor

Lipoprotein(a), or Lp(a), is a genetic particle linked to increased cardiovascular disease risk, affecting one in five people globally. Despite its significant impact, Lp(a) is not widely tested due to the lack of approved treatments, though this is changing with new drugs in development. Experts recommend testing for Lp(a) as part of cardiovascular risk assessment, especially for those with a family history or other risk factors, to encourage lifestyle changes that can mitigate overall heart disease risk.

via Fortune|

#cardiovascular-disease #cholesterol #genetics

health1 year ago•6 min saved

Unveiling Lipoprotein(a): The Overlooked Heart Risk Factor

Lipoprotein(a), or Lp(a), is a genetic particle linked to increased cardiovascular disease risk, affecting 1 in 5 people globally. Despite its significant impact, Lp(a) is not widely tested due to the lack of treatment options, though this is changing with new drugs in development. Experts recommend testing for Lp(a) to better manage overall heart health, especially for those with a family history of heart disease or other risk factors. Awareness and testing are crucial as Lp(a) levels are not influenced by lifestyle changes like LDL cholesterol.

via Fortune|

#cardiovascular-disease #cholesterol #genetics

health2 years ago•15 min saved

"Rethinking Cholesterol: Expert Insights and Life-Saving Tests"

Recent research suggests that the traditional understanding of cholesterol and its impact on cardiovascular health may be incomplete. While statins have been effective in lowering LDL cholesterol levels, they do not address other problematic cholesterol types such as lipoprotein(a) and remnant cholesterol. New medications targeting these cholesterol types are being researched, with the hope of reducing the risk of cardiovascular disease. Additionally, the role of HDL cholesterol is more complex than previously thought, and efforts to raise its levels have not shown significant health benefits. The emerging consensus is to minimize non-HDL cholesterol for better cardiovascular health.

via Inverse|

#cardiovascular-disease #cholesterol #hdl-cholesterol

health2 years ago•6 min saved

"The Overlooked Red Flag in Assessing Heart Attack Risk, According to Doctors"

Lipoprotein(a) (Lp(a)), a protein that can significantly increase the risk of heart attack when present in high levels in the blood, is often overlooked as a red flag for heart disease. Lp(a) causes atherosclerosis, inflammation, and increases the risk of clotting, making it a triple threat. Despite its prevalence and impact on cardiovascular health, only a small percentage of Americans have had their Lp(a) levels checked. While there is currently no therapeutic available to reduce Lp(a) levels, it is still important to test for it as it can help identify individuals at higher risk and allow for the mitigation of other cardiovascular risk factors. Researchers are actively studying Lp(a) and developing potential therapeutics to reduce its risk in the future.

via Yahoo News|

#cardiovascular-health #genetic-risk-factor #health

health2 years ago•2 min saved

Oral Drug Shows Promise in Reducing Heart-Disease Marker and 'Bad Cholesterol'

In a promising early trial, the experimental drug muvalaplin has shown the ability to reduce levels of lipoprotein(a) (Lp(a)), a molecule linked to cardiovascular disease, by up to 65%. Lp(a) is known to clog blood vessels and is difficult to reduce through diet or medication. Muvalaplin disrupts the formation of Lp(a) and was found to be well-tolerated with no serious adverse effects. Further clinical trials are underway to determine the drug's overall efficacy and long-term risks.

via ScienceAlert|

#cardiovascular-disease #clinical-trial #health